Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dolutegravir 50 mg Clear all
Completed Phase 3 Interventional Results available

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

NCT01227824
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

NCT01967771
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, CBZ
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

NCT02263326
View directory record Official record
Conditions
HIV Infection
Interventions
dolutegravir, lamivudine, Continue current antiretroviral regimen
Drug
Lead sponsor
Babafemi Taiwo
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Hepatic Impairment Study

NCT01231529
View directory record Official record
Conditions
Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1349572
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

NCT02422797
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

NCT02519777
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo for maraviroc (MVC), Placebo for dolutegravir (DTG), Dolutegravir (DTG), Maraviroc (MVC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

NCT03984838
View directory record Official record
Conditions
HIV Infections
Interventions
JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

NCT03816696
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

NCT02105987
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
ABC/DTG/3TC FDC, Ongoing cART regimen
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
87
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

NCT02582684
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Dolutegravir, Lamivudine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 25, 2026, 10:37 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Bioequivalence of a Combined Formulated Tablet

NCT01622790
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

NCT04857892
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, DTG, GSK3640254/DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 25, 2026, 10:37 PM EDT
Active, not recruiting Phase 4 Interventional

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

NCT02656511
View directory record Official record
Conditions
HIV
Interventions
Dolutegravir, Emtricitabine/Tenofovir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

NCT01499199
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

NCT01302847
View directory record Official record
Conditions
HIV Infections
Interventions
DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Weeks to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2011 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT02397694
View directory record Official record
Conditions
HIV-1 Infection
Interventions
BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

NCT02384395
View directory record Official record
Conditions
HIV, Acute HIV Infection
Interventions
Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

Rapid HIV Treatment Initiation, Access and Engagement in Care

NCT03512964
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Dolutegravir 50 MG, Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

NCT03547908
View directory record Official record
Conditions
HIV-1/HBV Co-Infection
Interventions
B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

NCT01209065
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Fosamprenavir, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 25, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

NCT00708110
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Bakersfield, California • Long Beach, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 25, 2026, 10:37 PM EDT